Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients.
North African
Poliosis
Uveitis
Vogt-Koyanagi-Harada
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
07 Oct 2020
07 Oct 2020
Historique:
received:
11
09
2019
accepted:
23
09
2020
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
15
5
2021
Statut:
epublish
Résumé
East and South East Asian subjects as well as Amerindians and Hispanic subjects are predominantly affected by Vogt-Koyanagi-Harada disease. In Europe, only few studies have described the clinical features and treatment of this disease, especially in France. This retrospective case series was based on data collected from patients with a VKH disease diagnosed from January 2000 to March 2017, provided by three French Tertiary Centers. Forty-one patients (16 men and 25 women) were diagnosed: average age at diagnosis was 38.7 years. Patients were mainly from Maghreb (58%), but ethnic origins were multiple. Pleiocytosis was observed in 19 cases (63%) and 17 out of 41 patients showed audio vestibular signs (41%), and 11 showed skin signs (27%). Thirty-four were treated with corticosteroids (83%), 11 with an immunosuppressant treatment (27%) and 5 with biological therapy drugs (13%). Relapse was observed in 41% patients, even though final average visual acuity had improved. We did not find any significant clinical difference in the population from Maghreb compared to other populations, but for age and sex trends, since there was a majority of younger women. We report here the second largest French cohort reported to date to our knowledge. The multiethnicity in our study suggests that VKH disease should be evoked whatever patients' ethnicity.
Sections du résumé
BACKGROUND
BACKGROUND
East and South East Asian subjects as well as Amerindians and Hispanic subjects are predominantly affected by Vogt-Koyanagi-Harada disease. In Europe, only few studies have described the clinical features and treatment of this disease, especially in France.
METHODS
METHODS
This retrospective case series was based on data collected from patients with a VKH disease diagnosed from January 2000 to March 2017, provided by three French Tertiary Centers.
RESULTS
RESULTS
Forty-one patients (16 men and 25 women) were diagnosed: average age at diagnosis was 38.7 years. Patients were mainly from Maghreb (58%), but ethnic origins were multiple. Pleiocytosis was observed in 19 cases (63%) and 17 out of 41 patients showed audio vestibular signs (41%), and 11 showed skin signs (27%). Thirty-four were treated with corticosteroids (83%), 11 with an immunosuppressant treatment (27%) and 5 with biological therapy drugs (13%). Relapse was observed in 41% patients, even though final average visual acuity had improved. We did not find any significant clinical difference in the population from Maghreb compared to other populations, but for age and sex trends, since there was a majority of younger women.
CONCLUSION
CONCLUSIONS
We report here the second largest French cohort reported to date to our knowledge. The multiethnicity in our study suggests that VKH disease should be evoked whatever patients' ethnicity.
Identifiants
pubmed: 33028239
doi: 10.1186/s12886-020-01656-x
pii: 10.1186/s12886-020-01656-x
pmc: PMC7539440
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
395Références
Clin Exp Med. 2016 May;16(2):125-36
pubmed: 25820692
J Fr Ophtalmol. 1998 Dec;21(10):746-54
pubmed: 10052048
Ophthalmology. 2003 Jan;110(1):15-21; quiz 22-3
pubmed: 12511340
Am J Ophthalmol. 2001 May;131(5):599-606
pubmed: 11336934
Ophthalmology. 2017 Dec;124(12):1799-1807
pubmed: 28689898
J Curr Ophthalmol. 2018 Dec 13;31(1):1-7
pubmed: 30899839
Int Ophthalmol. 2007 Apr-Jun;27(2-3):125-30
pubmed: 17203358
Ophthalmologica. 1990;201(3):162-7
pubmed: 2089358
Am J Ophthalmol. 2009 May;147(5):811-5
pubmed: 19232559
J Fr Ophtalmol. 2005 Jan;28(1):9-16
pubmed: 15767894
Autoimmun Rev. 2014 Apr-May;13(4-5):550-5
pubmed: 24440284
Int Ophthalmol. 2007 Apr-Jun;27(2-3):87-95
pubmed: 17253112
Graefes Arch Clin Exp Ophthalmol. 2015 May;253(5):785-90
pubmed: 25592477
Nippon Ganka Gakkai Zasshi. 1999 Apr;103(4):289-96
pubmed: 10339973
Eye (Lond). 2009 Mar;23(3):543-8
pubmed: 18369377
Am J Ophthalmol. 2006 Jul;142(1):119-24
pubmed: 16815259
Am J Ophthalmol. 1977 May;83(5):735-40
pubmed: 868972
Ocul Immunol Inflamm. 2006 Apr;14(2):71-2
pubmed: 16597535
J Glaucoma. 2016 Aug;25(8):674-80
pubmed: 26967258
Orphanet J Rare Dis. 2016 Mar 24;11:29
pubmed: 27008848
Am J Ophthalmol. 2001 May;131(5):647-52
pubmed: 11336942
Acta Ophthalmol. 2015 Sep;93(6):e475-80
pubmed: 25565265
Surv Ophthalmol. 1995 Jan-Feb;39(4):265-92
pubmed: 7725227
Sci Rep. 2014 Nov 10;4:6887
pubmed: 25382027
Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):3-8
pubmed: 18379934
Rev Med Interne. 2007 Apr;28(4):250-4
pubmed: 17350144
Acta Ophthalmol. 2011 Jun;89(4):e357-66
pubmed: 21251241
Acta Ophthalmol. 2017 Feb;95(1):85-90
pubmed: 27535102
Ocul Immunol Inflamm. 2006 Apr;14(2):87-90
pubmed: 16597537
Autoimmun Rev. 2013 Sep;12(11):1033-8
pubmed: 23567866
J Fr Ophtalmol. 2004 Nov;27(9 Pt 1):1013-6
pubmed: 15557863
Arch Soc Esp Oftalmol. 2018 May;93(5):225-230
pubmed: 29258782
Am J Ophthalmol. 1996 Dec;122(6):889-91
pubmed: 8956647
Rev Med Interne. 2015 Feb;36(2):107-16
pubmed: 25239400
JAMA Ophthalmol. 2017 Jun 1;135(6):511-518
pubmed: 28426849
Retina. 2010 Jan;30(1):33-41
pubmed: 20010321